Drug intelligence / Profile preview

tongluo huatan capsule

Development stage: Unknown
Lead developer: Shandong Wohua Pharmaceutical
Administration: Oral

Overview

Tongluo Huatan Capsule (通络化痰胶囊) is a traditional Chinese medicine (TCM) product developed and marketed by Shandong Wohua Pharmaceutical. It is an oral capsule indicated for the treatment of cerebrovascular disorders, particularly those associated with the TCM syndrome of phlegm blockage. The formulation is designed to dredge the collaterals (Tongluo) and transform phlegm (Huatan), addressing symptoms related to stroke and other cardiovascular or nervous system conditions. While the specific herbal composition is proprietary, the drug is approved in China for clinical use and is part of the company's portfolio for managing cardiovascular and neurological health.

Brand names: Tongluo Huatan Capsule通络化痰胶囊
Other names: Tongluo Huatan Jiaonang

Beyond the preview

Go deeper on tongluo huatan capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tongluo huatan capsule.

Explore the full profile